This CME Activity has expired and is no longer available for credit.
Mission: Pain Management—The Efficient First Visit
Patient Case Simulations
Time to Complete
November 27, 2012
November 27, 2013
1.00 / AMA PRA Category 1 Credit(s)TM 1.00 / CE for Nurses 1.00 / CE for Pharmacists
This activity is jointly sponsored by the University of Cincinnati, Advancing Knowledge in Healthcare (AKH Inc.), and Educational Awareness Solutions.
This activity is supported by educational grants provided by Purdue Pharma, L.P. and Mallinckrodt, the Pharmaceuticals business of Covidien.
Mission: Pain Management – The Efficient First Visit an IDEAL® Clinical Encounter is designed to help the pain team focus their efforts on maximizing their time with the chronic pain patient.
After reviewing relevant first visit “clinical pearls”, the expert faculty will interact with a chronic pain patient, discussing his history and current situation. They will then review management choices and appropriate treatments based upon the information and “clinical pearls” revealed earlier in the program. Throughout the activity, participants will have the opportunity to monitor their learning progress, via question and answer and the experts will provide evidence-based information that can be implemented immediately to enhance your patient care.
The educational design of this activity addresses the needs of physicians, nurses, pharmacists, and other health care professionals involved in the treatment of patients with pain.
After taking part in this educational activity, participants should be better able to:
Differentiate the underlying pathophysiology and pain transmission mechanisms associated with nociceptive, neuropathic, and centrally mediated chronic pain.
Compare non-pharmacologic and pharmacologic treatment options for chronic pain and contrast their relative risks and benefits in the management of chronic pain.
Illustrate barriers to the optimal use of opioid analgesics in patients with chronic pain and formulate strategies to address such barriers.
Assess therapeutic management methods, including titration for safety and efficacy, for screening and risk mitigation in the initial and follow-up care of patients with chronic pain.
Faculty Editorial Board
Bill H. McCarberg, MD Founder of the Chronic Pain Management Program Kaiser Permanente, San Diego Escondido, CA
Bill H. McCarberg, MD Speakers bureau: Endo Pharmaceuticals, NeurogesX, PriCara, Purdue Pharma
Jeffrey A. Gudin, MD Director, Pain and Palliative Care Englewood Hospital and Medical Center Englewood, NJ
Jeffrey A. Gudin, MD Speakers bureau: Pfizer Inc., Purdue Pharma, Johnson & Johnson Pharmaceuticals, Covidien, ProStrakan
Paul Arnstein, RN, PhD, FAAN Clinical Nurse Specialist for Pain Relief Massachusetts General Hospital Boston, MA
Paul Arnstein, RN, PhD, FAAN Nothing to disclose
John F. Peppin, DO, FACP Associate Medical Director Hospice of the Bluegrass Palliative Care Center of the Bluegrass Director, Center for Bioethics Pain Management and Medicine Clinical Associate Professor University of Kentucky Lexington, KY
John F. Peppin, DO, FACP Consultant/independent contractor: AIT Laboratories; Ameritox Laboratories; Astellas Pharma Inc.; Eli Lilly and Co.; NeurogesX; Progenics Pharmaceuticals, Inc.; Pfizer Inc.; Shinogi Inc.; Theravance, Inc.; Trevena, Inc. Speakers bureau: AIT Laboratories, Ameritox Laboratories, Astellas Pharma, Covidien Pharmaceuticals, NeurogesX, Progenics Pharmaceuticals Honoraria: AIT Laboratories, Ameritox Laboratories, Astellas Pharma, Covidien, NeurogesX, Progenics Pharmaceuticals Research support: Alpharma Pharmaceuticals; Arcion Therapeutics, Inc.; AstraZeneca Pharmaceuticals;Cephalon, Inc.; Johnson & Johnson Pharmaceuticals; King Pharmaceuticals; Megan Medical; NeurogesX; Pfizer; Progenics Pharmaceuticals; Sangamo BioSciences, Inc.
Mary Lynn McPherson, PharmD, BCPS, CPE Professor and Vice Chair, Dept Pharmacy Practice & Science University of Maryland School of Pharmacy Baltimore, MD
Mary Lynn McPherson, PharmD, BCPS Nothing to disclose
Planners and Managers Disclosures
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Luciano Acevedo, EAS, Nancy Feiwel, MD, EAS, Barbara Forney, UC, James Miller, EAS, Pearl Schwartz, EAS, Susan Tyler, M.Ed., CMP, CCMEP, UC, Liz Adams, AKH Inc., Jessie Goldman, AKH Inc., and Mimi Holman, AKH Inc., have nothing to disclose.
Web-based interactive CME program
AMA PRA Category 1 Credit(s)TM
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of Cincinnati, Advancing Knowledge in Healthcare (AKH Inc.), and Educational Awareness Solutions. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.
The University of Cincinnati designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CE for Nurses
AKH Inc. is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s COA.
AKH Inc. designates this educational activity for 1.00 contact hour (0.1 CEU). Accreditation applies solely to educational activities and does not imply approval or endorsement of any commercial product by the ANCC-COA.
CE for Pharmacists
AKH Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
AKH Inc. approves this application based activity for 1.00 contact hour (0.1 CEU). UAN 0077-9999-12-032-H04-P.
Faculty Disclosure Declaration According to the disclosure policies of the University of Cincinnati College of Medicine and AKH Inc., all faculty, planning committee members, and other individuals who are in a position to control content are required to disclose any relevant relationships with any commercial interest related to this activity. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity, and levels of evidence. Disclosure will be made at the time of activity.
Learner Assurance Statement The University of Cincinnati and AKH Inc. are committed to managing all conflict-of-interest issues that could arise as a result of prospective faculty members’ significant relationships with drug or device manufacturer(s). The University of Cincinnati and AKH Inc. are committed to retaining only those speakers with financial interests that can be reconciled with the goals and educational integrity of the CME/CE activity.
Method of Participation There are no fees for participating and receiving CME credit for this activity. During the period November 27, 2012 through November 27, 2013, participants must 1) read the complete program information, learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the online post-test by selecting the best answer to each question, and 4) complete the online evaluation form.
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed post-test with a score of 80% or better. Post-tests should be completed no later than November 27, 2013.
For information about the CME accreditation of this program, please contact Barb Forney of the University of Cincinnati at 513-558-3197 or firstname.lastname@example.org.
For information about the nursing and pharmacy accreditation of this program, please contact Jessie Goldman at AKH Inc. at (904) 683-8843 or via email at email@example.com.